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identify the direct costs, including costs for drugs and medical services, and indi-
rect costs, including loss productivity, loss of work, cost for accommodation and 
transportation due to treatment and other costs of patient and caregivers. Results: 
Annual total cost per patient with asthma accounts for 6,618,682 VND, from which 
direct costs are 2.5 times more than indirect cost (4,738,682 vs 1,880,000 VND). The 
total cost of asthma has increased following the asthma severity with 4,960,278; 
8,098,156; 10,759,234; 13,196,280 VND in mild, intermittent, moderate and severe 
asthma rate. In the structure of total cost, following the asthma severity, the per-
centage of direct costs increases and indirect costs decreases especially in the mild 
rate. Total economic burden of asthma was 23,165 billion VND, from which 71.5% 
(16,585 billion VND) are for direct costs and 29.5% (6,580 billion VND) for indirect 
cost. ConClusions: The economic impact of asthma (23,165 billion VND) on asth-
matic patients, families and society is significant. According to the study, putting 
more public health efforts to better control asthma is the first necessary step to 
reduce the costs of asthma.
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objeCtives: The aim of this study is to assess health care expenditure by disease 
in order to provide detailed analyses of resource allocations for 2012, based on 
the French health care system database. Methods: Using information about 
60 millions of individuals from the general scheme insurance database (85% of 
the French population), we identified all people who received care for each of 56 
groups of diseases or medical events or treatments, which are frequent, severe 
and/or costly. Algorithms have been applied to each patient, using ICD-10 diag-
noses for long-term chronic diseases or hospital stays, specific drugs or medical 
procedures. Costs of all reimbursed expenditures (outpatient/inpatient care, dis-
ability/sickness benefits) were extracted per individual for a top-down method 
allocated expenditure to each of the 56 diseases based on the average expendi-
ture by disease calculated for individuals with only one disease. All expendi-
tures were thereafter extrapolated to the whole population to fit national health 
account aggregates. Results: Among the 146 billion euros of expenditures (all 
insurance schemes), 22.1 billion (15%) were related to psychiatric disorders and 
treatments, 14 (10%) to cancer, 14.6 (10%) to cardiovascular diseases, 7.5 (5%) to 
diabetes, 6.6 (5%) to vascular-risk treatments, 6.1 (4%) to neurologic disorders, 3.5 
(2%) to chronic respiratory diseases, 4.7 (3%) to inflammatory/rare diseases/HIV, 
3.5 (2%) to treated chronic renal insufficiency, 1.4 (1%) to liver/pancreas diseases, 
1.5 (1%) to chronic pain killer users and 4 (3%) to other long-term chronic diseases. 
Isolated hospitalizations represented 32.8 billion € (23%), basic care 14.6 (10%) and 
maternity 9.1 (6%). This analysis also provides detailed patterns of expenditures by 
diseases. ConClusions: Our study provides helpful information to policy mak-
ers by monitoring the performance of the health care system at a disease-based 
level. This tool will be used to forecast the impact of ageing and epidemiologic 
patterns on health expenditures.
PCN79
THE BurdEN of HEalTH CarE CosTs assoCiaTEd wiTH ProsTaTE CaNCEr 
iN irElaNd
Burns R.M.1, Leal J.1, Wolstenhome J.1, O’Neill C.2, Sullivan F.J.3, Drummond F.J.4, Sharp L.4
1University of Oxford, Oxford, UK, 2NUI Galway, Galway, Ireland, 3Prostate Cancer Institutue, 
Galway, Ireland, 4National Cancer Registry Ireland, Cork, Ireland
objeCtives: In 2010,3, 230 men were diagnosed with prostate cancer (PCa) in 
Ireland, yielding one of the highest incidence rates across Europe. The focus of this 
paper was to derive average costs for PCa diagnosis, treatment and follow-up, and 
to estimate the overall health care expenditure for PCa in 2010 in Ireland using 
a quasi, incidence-based, bottom-up approach. Methods: PCa (ICD10 C61) inci-
dence and treatment data during 2007-2010 was obtained from the National Cancer 
Registry Ireland. Estimates of resource use for items not recorded by the NCRI were 
sourced from the literature and expert opinion. Costs associated with detection, 
diagnosis, treatment, treatment complications, follow-up until year 4 post-diagnosis 
and terminal care were estimated using various sources including study-specific 
survey data, Irish hospital costs (HSE Casemix) and costs published in the literature. 
A payer’s perspective using direct costs was adopted and costs were reported in 
2010€ . Results: The overall expenditure associated with prostate specific antigen 
(PSA) testing for those diagnosed with PCa in 2010 was € 360,016 (average per patient 
cost (APPC) € 56 (confidence interval (CI): € 45, € 67)). Diagnosis including biopsies 
and staging was estimated at € 2,872,333 (APPC € 804 (CI: € 573, € 1,114)). Treatment 
costs (for the first year) varied considerably with active surveillance estimated at 
€ 423,106 (APPC € 655 (CI: € 520, € 814)), external beam radiation therapy (in particular 
intensity-modulated radiation therapy) estimated at € 8,872,037 (APPC € 6,867 (CI: 
€ 5,429, € 8,235) and radical prostatectomy estimated at € 3,549,864 (APPC € 7,327 (CI: 
€ 5,797, € 8,787). The total burden of health care expenditure associated with PCa in 
2010 was approximately € 46.9 million (CI: € 37.4m, € 56.6m). ConClusions: PCa 
expenditure is substantial and represents a sizeable proportion of the Irish health 
care budget (€ 11bn). PCa incidence has steadily increased since 1998 due to increas-
ing PSA testing; should trends continue expenditure will increase and this will have 
implications for resource allocation in Ireland.
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reported were also considered for costing and values were derived from Tables 
Simpro and CBHPM. Exchange rate used was 1.00USD = 2.20BRL. Results: A total 
of 233 patients with lung cancer were identified at the database from which 101 were 
eligible to the study. Fifteen different chemotherapy regimens were reported. The 
most common regimen was carboplatin with pemetrexed (29,7%), 20,8% received 
bevacizumab containing regimen and only 6% were in use of oral chemotherapy. 
About 87% of the patients received a total of 3 cycles of treatment. Costs per cycle of 
the schemes observed ranged from US$ 11.890,36 to US$ 1.712,95. Considering the 
number of cycles administered reported in the database, the average cost of manage-
ment for one patient with metastatic NSCLC in 1L is US$19.001,79. ConClusions: 
Treatment of 1L metastatic NSCLC represents a significant burden to the Brazilian 
private payers. The preferences of chemotherapy regimens may change in the fol-
lowing years due to the incorporation of oral chemotherapy in the list of mandatory 
coverage treatments and procedures.
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objeCtives: To assess the management and associated lifetime costs in 
uMM patients as from the diagnosis of unresectable metastatic disease until 
death. Methods: We performed a retrospective patient chart review to obtain 
data on medical consumption related to the management of uMM. A complete 
registry of all patients diagnosed with melanoma at UZA between 2007 and May 
2014 was compiled. Eligible for this retrospective chart review were patients with 
uMM with sufficient data available and who deceased before May 2014. Data on 
demographics, disease characteristics and management of uMM were collected. 
Direct costs were calculated by multiplying each item of resource use with its 
unit cost (2013, € ) using the Belgian public health care payer’s perspective (PHCP) 
and patient’s perspective. Average (bootstrap 95%CI) overall costs per patient 
were calculated. Results: 396 patients were registered. 44 eligible patients were 
included. 81.8% (n= 36) of patients were treated by systemic treatment (s) of which 
13.6% (n= 6) received up to 4 different treatment lines. 14 patients received “new 
drugs” (ipilimumab: 13; vemurafenib: 4) 48/145 (40%) hospitalizations were for 
treatment administration. Mean overall cost/patient was € 45,297 (bootstrap 95% 
CI: 33,905- 57,550), of which € 44,346 (95%CI: 33,098-56,584) was reimbursed. The 
PHCP cost was driven by systemic treatments costs (51% of cost). Mean PHCP cost 
was € 93,537 (95 % CI: 81,710-105,346) for patients treated with “new drugs”, € 26,564 
(95 % CI: 20,688-32,999) for patients treated with chemotherapy but no “new drugs” 
and € 7,394 (95 % CI: 5,490-9,472) for patients on best supportive care (BSC) only. 
Median overall survival was 6.1 months (9 months, 5.2 months, and 1 month for 
patients treated with “new drugs”, with chemotherapy only, and with BSC only, 
respectively). ConClusions: Management of uMM results in considerable costs 
for the PHCP, mainly driven by systemic treatment costs.
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objeCtives: Breast cancer or rather called mastocarcinoma, is a malignant growth of 
the mammary gland. With an incidence rate of 5.105 people in 2010, breast cancer is 
the most frequent cancer disease in Austria. Annually about 1.500 cases of death are 
registered, therefore breast cancer is the leading cause for death among women. As a 
result, enormous costs arise for the health care system. Hence, the aim of the analysis 
was to evaluate the cost and disease burden of breast cancer. Methods: A burden of 
disease study, which evaluates all kinds of disease burden, like costs, quality adjusted 
life years (QALYs) and disability adjusted life years (DALYs) lost, was conducted. This 
analysis had an incidence based approach and projects costs over a time horizon of 
one year. Data were collected via literature review, published list prices and hospital 
records. Costs from published sources were used from the societal perspective. The 
direct costs include hospital, treatment and physician consultation costs. Indirect 
costs cover patient care giver costs as well as work absenteeism. Results: Each 
breast cancer patient causes direct costs of 6,423.91 EUR and indirect costs of 37,511.87 
EUR. Due to the fact that not only costs are important for the health care systems, 
the mortality rate, QALYs and DALYs were identified. The mortality rate of breast 
cancer conducts 7.7 percent of all cancer deaths in Austria. Compared to the healthy 
population, a breast cancer patient has average utility decrements of 0.11. With 
regard to an incidence rate of 5.105 people in 2010, a breast cancer patient will lose 
0.03 DALYs within one year. ConClusions: The analysis showed that the treatment 
of new diagnosed breast cancer patients causes about 225.5 million EUR. Moreover 
patients had a lower QALY of 561,55 and a loss of 153,15 DALYs within one year.
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objeCtives: Nowadays, health care costs of asthma are under pressure in all coun-
tries due to high prevalence, incidence and the chronic nature of disease. Estimating 
the economic burden of asthma from patients’ perspective is necessary not only to 
understand the value and structure, but also the economic influence of asthma to 
whole society to propose and implement the relevant medical. This is also the aim 
of this study. Methods: A tree-decision model has been developed to estimate the 
value and structure of the economic burden of asthma in Vietnam. The economic 
burden of asthma has been evaluated based on cost of asthma, including direct 
and indirect costs. A cohort of 227 asthma patients was selected to be surveyed to 
